Effects of atorvastatin on serum lipids, lipoproteins, and hemostasis.
Serum levels of lipids and lipoproteins were examined in individuals with hyperlipidemia treated with atorvastatin or colestimide and in healthy volunteers. Modified low-density lipoprotein (LDL) was measured by its faster electrophoretic mobility and expressed as charge modification frequency (CMF). Serum levels of total cholesterol (t-chol), triglyceride (TG), very low-density lipoprotein (VLDL)-chol, low-density lipoprotein (LDL)-chol, and CMF were significantly higher in hyperlipidemia, but there was no significant difference in serum high-density lipoprotein (HDL)-chol levels between hyperlipidemic and healthy subjects. Treatment with atorvastatin resulted in significant decreases of serum t-chol, TG, and LDL-chol levels but not serum HDL-chol and VLDL-chol. Treatment with colestimide significantly reduced serum t-chol, HDL-chol, and LDL-chol levels but not those of TG and VLDL-chol. CMF was significantly reduced by treatment with atorvastatin but not by colestimide. Atorvastatin significantly reduced plasma levels of thrombomodulin, thrombin antithrombin complex (TAT) and tissue type plasminogen activator-plasminogen activator inhibitor-I complex. Colestimide moderately prolonged activated partial thromboplastin time and reduction of TAT. Based on its actions of lowering modified LDL and improving hemostatic abnormalities, we postulate that atorvastatin might inhibit the onset of ischemic diseases.
Kushiya
Fumihiko
F
Second Department of Internal Medicine, Mie University School of Medicine, Tsu City, Japan.
Wada
Hideo
H
Ooi
Kinue
K
Sakurai
Yuko
Y
Sakaguchi
Akane
A
Noda
Maki
M
Abe
Yasunori
Y
Nakasaki
Takahiro
T
Tsukada
Tetsuya
T
Shiku
Hiroshi
H
Nobori
Tsutomu
T
D000328:Adult; D000368:Aged; D000837:Anion Exchange Resins / Q000627:therapeutic use; D000069059:Atorvastatin; D004587:Electrophoresis, Agar Gel; D004811:Epichlorohydrin; D005260:Female; D006487:Hemostasis / Q000187:drug effects*; D006538:Heptanoic Acids / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000097:blood*; D007093:Imidazoles; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000627:therapeutic use*; D012117:Resins, Synthetic
D000837:Anion Exchange Resins; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007093:Imidazoles; D008055:Lipids; D008074:Lipoproteins; D011758:Pyrroles; D012117:Resins, Synthetic; C417427:colestimide; D004811:Epichlorohydrin; D000069059:Atorvastatin